[{"uuid": "09a89ab3-27b8-38f4-8029-3c2be06f51de", "title": "Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle\u2122\u00a0Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium\u2122", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/denali-therapeutics-announces-upcoming-presentations-130000491.html", "providerPublishTime": 1738242000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LqCNahvZg25QjYOhzkDKTw--~B/aD0zMzQ7dz0xMzAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 1302, "height": 334, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5nGh7LvdwEtXmFGi.IQw8A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "1d855811-8ae0-3fd7-9da6-9afff75c49dc", "title": "Amgen Set to Report Q4 Earnings: Is a Beat in the Cards?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/amgen-set-report-q4-earnings-161000994.html", "providerPublishTime": 1738167000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/._mAv70PW7IAFz5cM1Tjpg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pvIyyMXLKwAjR2pqQ29s0Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/65d4d9838ddb692fbe578219ce60c69d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AMGN"]}, {"uuid": "c7500fd7-1b0c-3bbb-90fe-2b1b5f351f73", "title": "Denali Gains 26.6% in a Year: How Should You Play the Stock?", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/denali-gains-26-6-play-111300399.html", "providerPublishTime": 1737457980, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/H9DYdttPy00EKBHhcxtlCA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/n5SbNKsJsCKv7joAIRd2zA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/9f2a2e04a053cda7a8c096e532e43d28", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI", "SNY"]}, {"uuid": "4485c033-1f84-3b93-bf57-8e0e12c72014", "title": "Why Denali Therapeutics (DNLI) Is the Biotech Stock with Biggest Upside Potential", "publisher": "Insider Monkey", "link": "https://finance.yahoo.com/news/why-denali-therapeutics-dnli-biotech-161802993.html", "providerPublishTime": 1737130682, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/CjocU9httX3S5RFki_omOQ--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/93666af8b48c4afcb5d2135ac5a3facc", "width": 1456, "height": 816, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/BA_AXAVHoTHanIOz_MXVAQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/93666af8b48c4afcb5d2135ac5a3facc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "949db464-db5b-3fb3-9ae7-67963b827ebd", "title": "DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/dnlis-hunter-syndrome-drug-gets-162000194.html", "providerPublishTime": 1736439600, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 635, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pa5q6Axi5bBp9pCuwXBcUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "38c677f0-ce73-3b1f-9fbf-8f2fbffd5b9a", "title": "Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/denali-therapeutics-announces-key-anticipated-130000321.html", "providerPublishTime": 1736773200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LqCNahvZg25QjYOhzkDKTw--~B/aD0zMzQ7dz0xMzAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 1302, "height": 334, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5nGh7LvdwEtXmFGi.IQw8A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "7d833c91-31b2-3c30-9aac-a211dc3a1d2e", "title": "Denali's ALS Study Fails to Meet Primary and Secondary Endpoints", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/denalis-als-study-fails-meet-191400678.html", "providerPublishTime": 1736277240, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887", "width": 620, "height": 413, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Y_dqyXeRF.XKTra8_Iy4.g--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI", "SNY"]}, {"uuid": "00f01da3-a5e2-36e1-8b71-351a0449d3a9", "title": "Denali Gets FDA Breakthrough Therapy Designation for Hunter Syndrome Treatment", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/denali-gets-fda-breakthrough-therapy-155144175.html", "providerPublishTime": 1736351504, "type": "STORY", "relatedTickers": ["DNLI"]}, {"uuid": "05175047-5a50-3c36-b58a-f9cf28265e4e", "title": "Denali Therapeutics price target lowered to $32 from $35 at BTIG", "publisher": "TipRanks", "link": "https://finance.yahoo.com/news/denali-therapeutics-price-target-lowered-122539522.html", "providerPublishTime": 1736339139, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/BemfyP1UBzXHKKZLDQ1ooQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/c37c6416e3d93ec36371ae85ba3ad4a9", "width": 192, "height": 192, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lHJgUudIejgjPs_lWQT1vQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/tipranks_452/c37c6416e3d93ec36371ae85ba3ad4a9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "3470a126-5749-36b7-9f89-5fd4f28abd60", "title": "Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/denali-therapeutics-announces-u-fda-130000083.html", "providerPublishTime": 1736341200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LqCNahvZg25QjYOhzkDKTw--~B/aD0zMzQ7dz0xMzAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 1302, "height": 334, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5nGh7LvdwEtXmFGi.IQw8A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "f03b1afe-f71e-3057-acac-2f27e67cc4f7", "title": "Denali Therapeutics Trial of Potential ALS Treatment Misses Primary, Secondary Endpoints; Shares Fall After Hours", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/denali-therapeutics-trial-potential-als-223028470.html", "providerPublishTime": 1736202628, "type": "STORY", "relatedTickers": ["DNLI"]}, {"uuid": "d2bf25ec-60b7-31aa-a5df-2e4ae6235ac1", "title": "Baird Initiates Denali Therapeutics at Outperform With $31 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/baird-initiates-denali-therapeutics-outperform-131720704.html", "providerPublishTime": 1736255840, "type": "STORY", "relatedTickers": ["DNLI"]}, {"uuid": "51067cab-6a7d-3ad3-aaff-1372f74ee69c", "title": "Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/denali-therapeutics-amyotrophic-lateral-sclerosis-174832467.html", "providerPublishTime": 1736272112, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/QGEcm6vkUF2v0ptY66HSsg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/68a6d3dc066609dcd69ea791184d981a", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/ppSzo9NiFrrPie6N_5wAUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/68a6d3dc066609dcd69ea791184d981a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "c0a4688d-2c44-35d0-9d72-6dd241fa1744", "title": "Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/denali-therapeutics-announces-topline-results-213000369.html", "providerPublishTime": 1736199000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/LqCNahvZg25QjYOhzkDKTw--~B/aD0zMzQ7dz0xMzAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 1302, "height": 334, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5nGh7LvdwEtXmFGi.IQw8A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "4bd39d21-2921-3164-b425-c731bfe5e65f", "title": "Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic", "publisher": "Benzinga", "link": "https://finance.yahoo.com/news/denali-therapeutics-neurodegenerative-disease-platform-180802032.html", "providerPublishTime": 1735927682, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HkMo6b1Ycaru4DvjhTHmKg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/12d9455f235bc8de9d9cd5cb9a4b0287", "width": 983, "height": 553, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/e2YmENxz6oOTv0CW4uLcAw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/12d9455f235bc8de9d9cd5cb9a4b0287", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "21752cf5-f1c7-3c71-8c61-a9bcf5b6879d", "title": "These Stocks Moved the Most Today: Nvidia, Micron, Aurora Innovation, Tesla, Carvana, Moderna, Palantir, and More", "publisher": "Barrons.com", "link": "https://finance.yahoo.com/m/21752cf5-f1c7-3c71-8c61-a9bcf5b6879d/these-stocks-moved-the-most.html", "providerPublishTime": 1736285580, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/_kc6REYMS1JrAuV5bYtjfA--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e", "width": 320, "height": 65, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/5waH37HKuL3X52B3V2GWrw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["NVDA", "MU", "UBER", "DNLI", "NARI", "FUBO"]}, {"uuid": "1e5788d2-c7cd-3614-af0f-9dff46084b69", "title": "Denali Reverses Its Fortunes With 'Too Early' Miss In ALS Treatment", "publisher": "Investor's Business Daily", "link": "https://finance.yahoo.com/m/1e5788d2-c7cd-3614-af0f-9dff46084b69/denali-reverses-its-fortunes.html", "providerPublishTime": 1736284091, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EZkMF9GXdAUBCc483e_hLQ--~B/aD01NjU7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/dd951202e75ce885dd3626d65a5055ff", "width": 1000, "height": 565, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/eIYjAMJ5B3Qq8rjQEfjKNg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/dd951202e75ce885dd3626d65a5055ff", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "cb521e0c-d782-3a19-8d77-c61932598fbe", "title": "Denali Therapeutics\u2019 ALS therapy fails to meet primary endpoint in Phase II/III trial", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/cb521e0c-d782-3a19-8d77-c61932598fbe/denali-therapeutics%E2%80%99-als.html", "providerPublishTime": 1736262782, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/mQwHoDLJDrN7wjmkOB4Kew--~B/aD05NTg7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/b10bff1ed38c24137963fe6953a4dc73", "width": 1440, "height": 958, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/87gnFBMKv4BVQgvVUDt16w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/b10bff1ed38c24137963fe6953a4dc73", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI"]}, {"uuid": "c485a834-59bf-3bcb-a838-4e23591fe7bd", "title": "ALS drugs from Denali, Calico come up short, marking setback for Healey trial", "publisher": "BioPharma Dive", "link": "https://finance.yahoo.com/m/c485a834-59bf-3bcb-a838-4e23591fe7bd/als-drugs-from-denali%2C-calico.html", "providerPublishTime": 1736242860, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/4ls5.DCdG8tU7K2I_2hvQA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/60cbb117f591d4716ef3b5d9362fc1c0", "width": 1600, "height": 900, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/xLwmYfEu3Za3xJI77U4U2Q--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/60cbb117f591d4716ef3b5d9362fc1c0", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["DNLI", "ABBV"]}, {"uuid": "9fce6d79-5aed-39c4-821a-bf684c6b7998", "title": "Block upgraded, Bumble downgraded: Wall Street's top analyst calls", "publisher": "The Fly", "link": "https://finance.yahoo.com/news/block-upgraded-bumble-downgraded-wall-143355618.html", "providerPublishTime": 1735914835, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/zUit8GQVW5kcaTZHEPMI9Q--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 1200, "height": 628, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/IPH9wCP.ftudEFOX7xr1MA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/the_fly_169/5039a5ccc6ec98e1b92bc672330bfcec", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["BMBL"]}]